37 results about "Dermatitis herpetiformis" patented technology

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the proteolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.

The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.

Disclosed are glutamine endopeptidase enzymes from Rothia sp. bacteria that are naturally associated with the oral cavity, formulations comprising the glutamine endopeptidase enzymes and the use thereof for the treatment, prevention of allergic reaction and diagnosis of gluten allergy related diseases such as Celiac Sprue, gluten allergy and/or dermatitis herpetiformis.

Celiac Sprue and/or dermatitis herpetiformis arc treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the protcolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinií (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency.

The invention is directed to a method of detecting gluten-induced diseases such as e.g. celiac disease and dermatitis herpetiformis. Said diseases are indicated by the presence of autoantibodies against tissue transglutaminase tTG in the blood The test is carried out on a whole blood sample using tTG liberated from the red blood cells of the blood sample as an autoantigen. The liberated autoantigens react with the autoantibodies in the sample and form antigen-antibody complexes, which are detected. The presence of such complexes indicates the disease. The invention is also directed to the use of the autoantigen in a test and to a test-kit.

Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases. It was found that autoimmune diseases other than celiac disease can be diagnosed and distinguished in this way, notably, dermatitis herpetiformis Duhring, Crohn's disease, Addison's disease, AI hemolytic anemia, AI thrombocytopenic purpura, AI thyroid diseases, atrophic gastritis—pernicious anemia, IgA nephropathy or IgA glomerulonephritis, myasthenia gravis, partial lipodystrophy, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, recurrent pericarditis, relapsing polychondritis, rheumatoid arthritis, rheumatism, sarcoidosis, Sjögren's syndrome, SLE, splenic atrophy, type I (insulin-dependent) diabetes mellitus, diabetes mellitus of other types, ulcerative colitis, vasculitis (both systemic and cutaneous), vitiligo as well as autoimmune diseases associated with infertility, increased risk of abortion, or reduced fetal growth.

The invention relates to a new family of proteolytic enzymes having the ability to hydrolize at a p H between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an Actinoallomurus strain. The object of the invention includes also methods for producing enzymes composition comprising the endopeptidases by cultivation of native Actinoallomurus strains, mutants thereof, or recombinant host cells comprising nucleic acids codifying for the endopeptidases. Said nucleic acids constitute a further object of the invention. The enzyme compositions comprising at least one endopeptidase of the invention are useful for the treatment and/or prevention of celiac sprue, dermatitis herpetiformis and any other disorder associated with gluten intolerance as ingredients of pharmaceutical formulations or as additives of foods and drinks.

A topical composition is prepared using macerated leaves of St. Andrew's Cross (hypericum hypericoides). An aqueous extract of the leaves is mixed with ethanol to form a spray or to saturate a wet wipe and administer to a mammal skin for treatment a variety of skin conditions, including eczema, psoriasis, rosacea, cellulitis, contact dermatitis, seborrhoeic dermatitis, nummular dermatitis, dandruff, stasis dermatitis, perioral dermatitis, dermatitis herpetiformis, ecthyma, impetigo, shingles, urticaria, tinea pedis, tinea manuum, tinea cruris, sunburn, insect bites and stings, jellyfish stings, granuloma annulare, bullous pemphigoid, lichen planus, bed sore, inflammations caused by waterborne vectors, diaper rash, heat rash, pityriasis rosea, jungle rot, scleroderma, skin rashes and photo-aging.

Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (TG2); which methods can include inhibiting the activation of TG2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, Crohn's Disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric tissues, in particular the paracellular transport of molecules greater than about 500 mw, e.g. peptides, including without limitation immunogenic gluten peptides.

The invention discloses a preparation method and application of an anti-herpes simplex virus complex IgY antibody, and belongs to the technical field of herpes simplex virus resisting. The preparationmethod includes the following steps that step 1, an immunogen is prepared, specifically, a herpes simplex virus type 1 and a herpes simplex virus type 2 are taken and mixed and then the mixture is mixed with a Freund's complete adjuvant and a Freund's incomplete adjuvant separately and stirred and emulsified to prepare a water-in-oil Freund's complete adjuvant and Freund's incomplete adjuvant herpes simplex virus immunogen; and step 2, immunity is performed, specifically, the Freund's complete adjuvant immunogen is injected into laying hens. Application to ocular conjunctiva, a nasal cavity and an oral cavity is achieved, no limitations and side effects of systemic medication exist, the local application taking effect is quick, the dosage is low, the curative effect is good, the normal micro-ecological environment on the surface of the conjunctiva, the nasal cavity and the oral cavity is not absorbed and damaged, no toxic and side effects exist, and diseases of herpes labialis, dermatitis herpetiformis and herpes zoster caused by the herpes simplex virus type 1 and the herpes simplex virus type 2 and viruses with a common antigen with the herpes simplex virus type 1 and the herpessimplex virus type 2 are prevented and treated.

The invention discloses application of single nucleotide polymorphism site rs2523607 to screening of patients suffering from dermatitis herpetiformis. A technical scheme protected by the invention is characterized in that application of a substance for detecting polymorphism or a gene type of the rs2523607 in a human genome to preparation of a product for screening the patients suffering from the dermatitis herpetiformis and application of the substance for detecting the polymorphism or the gene type of the rs2523607 in the human genome to preparation of a product for detecting single nucleotide polymorphism relevant to the dermatitis herpetiformis are provided. The substance for detecting the polymorphism or the gene type of the rs2523607 and other substances (for example, substances for detecting other single nucleotide polymorphism or gene types relevant to the dermatitis herpetiformis) are combined together to screen the patients suffering from dermatitis herpetiformis.